Exact Sciences Corporation

Equities

EXAS

US30063P1057

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 10:05:05 2024-04-25 am EDT			5-day change	1st Jan Change
59.66 ^USD	-5.67%		-6.19%	-19.51%

Apr. 17	Exact Sciences Corporation announced that it has received $266.75 million in funding	CI
Apr. 15	Sector Update: Health Care Stocks Advance Premarket Monday	MT

EXACT SCIENCES CORP : Other Events (form 8-K)

November 27, 2019 at 05:35 pm EST

der-top: Black 2pt solid; border-bottom: Black 1pt solid">

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):

Latest news about Exact Sciences Corporation

Exact Sciences Corporation announced that it has received $266.75 million in funding	Apr. 16	CI
Sector Update: Health Care Stocks Advance Premarket Monday	Apr. 15	MT
Exact Sciences Names Aaron Bloomer CFO	Apr. 15	MT
Exact Sciences Appoints Aaron Bloomer as Chief Financial Officer, Effective from May 15, 2024	Apr. 15	CI
Exact Sciences Corporation Announces Executive Changes	Apr. 15	CI
Exact Sciences Signs Debt Exchange Deal, Placement of Convertible Notes	Apr. 11	MT
Exact Sciences Corporation announced that it expects to receive $266.8 million in funding	Apr. 09	CI
Exact Sciences Corp. Advances Development of Non-Endoscopic Oncoguard Esophagus Test to Screen for Esophageal Cancer and Pre-Cancer	Mar. 28	CI
Transcript : Exact Sciences Corporation - Special Call	Mar. 14
Exact Sciences Insider Sold Shares Worth $287,500, According to a Recent SEC Filing	Mar. 05	MT
Transcript : Exact Sciences Corporation Presents at TD Cowen 44th Annual Health Care Conference 2024, Mar-04-2024 01:30 PM	Mar. 04
Exact Sciences Insider Sold Shares Worth $356,302, According to a Recent SEC Filing	Feb. 29	MT
Exact Sciences Insider Sold Shares Worth $305,963, According to a Recent SEC Filing	Feb. 23	MT
Transcript : Exact Sciences Corporation, Q4 2023 Earnings Call, Feb 21, 2024	Feb. 21
Earnings Flash (EXAS) EXACT SCIENCES Reports Q4 Revenue $646.9M, vs. Street Est of $639.7M	Feb. 21	MT
Exact Sciences Corporation Provides Earnings Guidance for the first quarter and Year 2024	Feb. 21	CI
Exact Sciences' Q4 Loss Narrows, Revenue Increases; Sets 2024 Revenue Forecast	Feb. 21	MT
Exact Sciences Corporation Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 21	CI
Transcript : Exact Sciences Corporation Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-08-2024 11:15 AM	Jan. 08
Exact Sciences Sees 17% Growth in Q4 Revenue	Jan. 08	MT
Exact Sciences Corporation Announces Jeff Elliott Plans to Step Down as Chief Financial Officer in 2024	Jan. 07	CI
Exact Sciences Corporation Provides Revenue Guidance for the Year Ended December 31, 2023 and 2024	Jan. 07	CI
Exact Sciences Corporation Announces Jeff Elliott Plans to Step Down as Executive Vice President	Jan. 07	CI
Benchmark Upgrades Exact Sciences to Buy From Hold, Sets Price Target at $91	Jan. 02	MT
Exact Sciences Corp. Presents Multiple Studies At San Antonio Breast Cancer Symposium Supporting Optimization and Individualization of Therapy for Breast Cancer Patients	Dec. 01	CI

	1st Jan change	Capi.
EXACT SCIENCES CORPORATION	-19.51%	11.48B
IOVANCE BIOTHERAPEUTICS, INC.	+38.44%	3.27B
GUARDANT HEALTH, INC.	-35.88%	2.2B
BGI GENOMICS CO., LTD.	-18.60%	2.05B
VERACYTE, INC.	-30.24%	1.49B
MARAVAI LIFESCIENCES HOLDINGS, INC.	+12.21%	1.01B
SEEGENE, INC.	-3.06%	743M
CAREDX, INC	-36.00%	413M
ADAPTIVE BIOTECHNOLOGIES CORPORATION	-48.37%	377M
CURIOX BIOSYSTEMS CO., LTD	+27.44%	374M

1st Jan change

Capi.

EXACT SCIENCES CORPORATION